ES2805724T3 - Compuestos de adenina conjugados y su uso como adyuvantes de vacunas - Google Patents

Compuestos de adenina conjugados y su uso como adyuvantes de vacunas Download PDF

Info

Publication number
ES2805724T3
ES2805724T3 ES16782095T ES16782095T ES2805724T3 ES 2805724 T3 ES2805724 T3 ES 2805724T3 ES 16782095 T ES16782095 T ES 16782095T ES 16782095 T ES16782095 T ES 16782095T ES 2805724 T3 ES2805724 T3 ES 2805724T3
Authority
ES
Spain
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
alkyl
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16782095T
Other languages
English (en)
Spanish (es)
Inventor
Hitoshi Ban
Yukihiro Nishio
Padma Malyala
Bilikallahalli K Muralidhara
Marcus Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Application granted granted Critical
Publication of ES2805724T3 publication Critical patent/ES2805724T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES16782095T 2015-09-29 2016-09-28 Compuestos de adenina conjugados y su uso como adyuvantes de vacunas Active ES2805724T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562234481P 2015-09-29 2015-09-29
PCT/JP2016/004375 WO2017056494A1 (en) 2015-09-29 2016-09-28 Adenine conjugate compounds and their use as vaccine adjuvants

Publications (1)

Publication Number Publication Date
ES2805724T3 true ES2805724T3 (es) 2021-02-15

Family

ID=57138095

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16782095T Active ES2805724T3 (es) 2015-09-29 2016-09-28 Compuestos de adenina conjugados y su uso como adyuvantes de vacunas

Country Status (8)

Country Link
US (1) US10597397B2 (https=)
EP (1) EP3355933B1 (https=)
JP (1) JP6764930B2 (https=)
CN (1) CN108348618B (https=)
CA (1) CA2998995A1 (https=)
DK (1) DK3355933T3 (https=)
ES (1) ES2805724T3 (https=)
WO (1) WO2017056494A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
CA3107409A1 (en) * 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
EP3936147A4 (en) * 2019-03-04 2022-09-28 JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases METHOD OF MANUFACTURE OF AN INFLUENZA HA-SPLIT VACCINE
EP3954382A4 (en) * 2019-04-05 2022-12-21 Sumitomo Pharma Co., Ltd. WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING IT
KR20250038769A (ko) * 2022-07-26 2025-03-19 자임워크스 비씨 인코포레이티드 면역조절제 퓨린 유래 화합물, 이의 접합체 및 이의 사용 방법
WO2024206402A1 (en) * 2023-03-27 2024-10-03 The Cleveland Clinic Foundation Topical pala therapy for cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
JP2007514644A (ja) 2003-04-10 2007-06-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応を向上させる方法および組成物
EP2939693A1 (en) 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
ES2552471T3 (es) * 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
ES2656813T3 (es) 2008-10-24 2018-02-28 Glaxosmithkline Biologicals Sa Derivados de imidazoquinolina lipidados
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
EP2461690A4 (en) 2009-08-07 2013-03-27 Glaxosmithkline Biolog Sa LIPIDED OXOADENINE DERIVATIVES
US20130202629A1 (en) * 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
WO2012011606A1 (en) * 2010-07-20 2012-01-26 Dainippon Sumitomo Pharma Co., Ltd. Process for preparing adenine compounds and intermediates thereof
ES2617451T3 (es) 2010-08-17 2017-06-19 3M Innovative Properties Company Composiciones lipidadas de compuestos modificadores de la respuesta inmunitaria, formulaciones, y métodos
FR2968662B1 (fr) * 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas

Also Published As

Publication number Publication date
JP2018529717A (ja) 2018-10-11
US10597397B2 (en) 2020-03-24
CN108348618B (zh) 2021-06-15
EP3355933A1 (en) 2018-08-08
CA2998995A1 (en) 2017-04-06
DK3355933T3 (da) 2020-07-20
HK1258252A1 (en) 2019-11-08
EP3355933B1 (en) 2020-05-06
WO2017056494A1 (en) 2017-04-06
CN108348618A (zh) 2018-07-31
US20180282334A1 (en) 2018-10-04
JP6764930B2 (ja) 2020-10-07

Similar Documents

Publication Publication Date Title
ES2805724T3 (es) Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
JP7195398B2 (ja) ピリミジン化合物
JP7169968B2 (ja) ワクチンアジュバント製剤
ES2891528T3 (es) Compuestos útiles como inmunomoduladores
ES3034676T3 (en) Inhibitors of arg1 and/or arg2
US10988500B2 (en) Lipid A mimics, methods of preparation, and uses thereof
Shariat et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
ES2848648T3 (es) Imidazoquinolinas pegiladas como agonistas de TLR7 y TLR8
BR112020006761A2 (pt) métodos para administrar agonistas de sting
Lin et al. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells
Kovacs-Nolan et al. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody-and cell-mediated immune responses in mice
KR20190008545A (ko) Tlr 작용제를 함유하는 제제 및 사용 방법
Li et al. Cell membrane adhesive n-hexadecyl choline phosphate as vaccine delivery systems for anticancer immunotherapy
KR20230026438A (ko) Tlr4 작동 활성을 갖는 아쥬반트
HK1258252B (en) Adenine conjugate compounds and their use as vaccine adjuvants
KR20210111170A (ko) 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
JP2025514198A (ja) 二重機能免疫調節化合物、製剤、及びその使用
JP2025072436A (ja) 動力学的制御が可能なアジュバントを含むmRNAワクチン